HNRNPA1 and cancer: An increasing number of targets, including RBPs such as HuR, hnRNPA1, IGFBP3, Sam68, DDX3, DHX9, and MBNL2, are under evaluation for the development of new cancer treatments [5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24].